Compounded Semaglutide in 2026: What the FDA Crackdown Means for You

In March 2026, the U.S. Food and Drug Administration (FDA) issued warning letters to more than 30 telehealth providers marketing compounded versions of semaglutide and tirzepatide for weight loss. The warning letters cite improper marketing claims, missing required disclosures, and in some cases, formulations that the FDA considers to be "essentially copies" of FDA-approved products — which is not permitted under federal compounding rules.

For patients currently using compounded GLP-1 medications, this enforcement action raises real questions about safety, legality, and continuity of care. This article walks through what changed, why, and what your options are.

Quick background: what is compounded semaglutide?

Compounded semaglutide is a non-FDA-approved version of the active ingredient in Ozempic and Wegovy, prepared by a licensed compounding pharmacy. It is typically sold at lower price points ($150-300/month) versus brand-name semaglutide ($1,000+/month retail).

Compounded medications exist in a legal carve-out: under section 503A of the Food, Drug, and Cosmetic Act, compounding pharmacies can produce non-FDA-approved formulations under specific conditions — most commonly to fill genuine clinical need that the FDA-approved version cannot meet.

What changed in 2025-2026

When the FDA placed semaglutide and tirzepatide on the official drug shortage list in 2022-2023, compounding pharmacies were permitted to produce compounded versions broadly. That ended in April 2025 (semaglutide) and March 2025 (tirzepatide) when the FDA declared the shortages resolved.

Compounding did not stop. Many pharmacies and telehealth providers continued, often by adding minor ingredients (e.g., vitamin B12, L-carnitine) to create "personalized" formulations they argue fall outside the "essentially a copy" prohibition. The FDA explicitly disagrees.

What the March 2026 warning letters say

The letters generally cite three categories of violations:

• Marketing compounded products as "the same as" FDA-approved medications
• Failing to include required risk disclosures
• Producing compounded formulations the FDA considers copies of FDA-approved drugs

Providers receiving warning letters typically have 15 working days to respond. Failure to comply can lead to injunctions, product seizures, and prescription restrictions.

What this means if you currently use compounded GLP-1

• Your supply may continue uninterrupted, but availability is increasingly uncertain.
• Many providers are pivoting to FDA-approved brand-name medications and may discontinue compounded offerings.
• If you have not had a recent medical evaluation, schedule one — your prescriber needs to assess whether brand-name options are appropriate.
• Compounded medications are not FDA-reviewed for safety or efficacy. Quality varies by compounding pharmacy.

What are your alternatives

For most patients, the highest-quality alternative is an FDA-approved brand-name GLP-1 medication. Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have introduced manufacturer-direct cash-pay programs that bring monthly costs down to $349-499 for those without insurance coverage.

Several telehealth providers (Hers, Ro, LifeMD) have formal partnerships with Novo Nordisk and Eli Lilly to deliver brand-name GLP-1 with consultation included, often in the $200-400/month range. These are FDA-approved formulations subject to full quality controls.

Bottom line

Compounded GLP-1 medications saved patients significant money during the shortage era, but the regulatory landscape has tightened. The safest path forward is to work with a licensed prescriber and prefer FDA-approved options when accessible. If cost remains the primary barrier, ask your provider about manufacturer assistance programs and manufacturer-direct cash-pay channels before considering compounded alternatives.